Bodycote plc Advances £80 Million Share Buyback with 153,538 Shares Repurchased at 667.4p Average Price

Overview of Bodycote's £80 Million Share Repurchase Programme

On 11 March 2026, Bodycote plc launched an £80 million share repurchase programme aimed at enhancing shareholder value through strategic capital returns. The programme is structured in tranches, with the initial £40 million phase currently underway and actively acquiring shares on the market. This capital allocation reflects the company’s confidence in its financial strength and commitment to returning value to shareholders while preserving operational flexibility. The March announcement provided shareholders with clear visibility on the scope and timing of the planned buyback activity.

Repurchases are systematically executed via Barclays Bank plc through on-exchange transactions adhering to London Stock Exchange regulations. This method ensures regulatory compliance and market transparency. The company’s commitment to weekly reporting of share purchases allows investors to monitor the programme’s progress in real time. Utilizing a leading financial institution as the executing broker ensures professional market execution and competitive pricing.

July 2026 Weekly Purchase Details and Price Range

During the week of 13 to 17 July 2026, Bodycote acquired 153,538 ordinary shares at prices ranging from 642.0p to 695.0p per share, with a volume weighted average price of 667.4p. Purchases were distributed proportionally to trading volumes over the week, reflecting normal intra-week price fluctuations. This data provides investors insight into the quality of execution and the value at which shares were repurchased.

All shares were bought as on-exchange transactions, ensuring purchases occurred in the ordinary course of trading on the London Stock Exchange rather than through negotiated block trades. This approach maintains market liquidity and prevents distortions in trading patterns. Detailed transaction data accompanying the announcement complies with Market Abuse Regulation Article 5(1)(b), offering full transparency on trade execution. Investors can evaluate whether the timing of purchases aligned favorably with the company’s share price movements.

Progress Toward £40 Million First Tranche Completion

Since the programme’s inception, Bodycote has cumulatively repurchased 2,264,016 ordinary shares for cancellation via Barclays Bank plc. The July 2026 purchase of 153,538 shares at an average price of 667.4p marks significant advancement toward completing the £40 million first tranche. Although the exact amount of capital deployed within this tranche has not been disclosed, ongoing weekly updates will provide transparency on progress and transition to subsequent phases.

The volume of weekly purchases demonstrates the company’s commitment to deploying capital at a substantial pace while adapting to market conditions. The programme’s flexible structure, with two £40 million tranches, allows Bodycote to adjust buyback timing based on share price trends and market environment, ensuring disciplined execution without overpaying.

Effect on Share Capital and Voting Rights After Cancellation

Following cancellation of the 2,264,016 repurchased shares, Bodycote’s issued ordinary share capital now totals 170,498,574 shares, representing the full voting rights in the company. The company holds no treasury shares, indicating all repurchased shares have been permanently cancelled. This permanent reduction in share count supports an increase in earnings per share (EPS) by lowering the denominator in EPS calculations.

For shareholders, the buyback-induced share count reduction potentially enhances EPS metrics, assuming stable earnings. This benefit will accumulate as further shares are repurchased and cancelled during the ongoing £40 million tranche and any future tranches. Investors should consider this factor when evaluating Bodycote’s EPS forecasts and guidance.

Compliance with Regulatory and Listing Requirements

This announcement complies with UK Listing Rule 9.6.6, which requires disclosure of share purchases made under approved buyback programmes. Providing detailed transaction-level data in line with Market Abuse Regulation Article 5(1)(b) exceeds minimum disclosure standards, ensuring comprehensive transparency for investors and regulators. This adherence underscores Bodycote’s commitment to governance and regulatory compliance.

Weekly reporting of share purchases exemplifies best practice in investor communication and regulatory transparency. Rather than quarterly or semi-annual disclosures, Bodycote’s frequent updates reduce information asymmetry and allow market participants to observe purchase timing relative to share price movements. The attached trade details enable verification of compliance with all applicable rules governing share buybacks.

Bodycote’s Business Profile and Capital Allocation Strategy

Bodycote plc specialises in thermal processing and advanced material treatments, serving aerospace, automotive, energy, and other industrial sectors worldwide. Operating a broad network of facilities, the company has established a strong market position through high-value technical services. The £80 million buyback programme reflects Bodycote’s confidence in its financial position and ability to generate cash flows supporting both capital returns and operational needs. The March 2026 announcement contextualises the company’s strategic shareholder value initiatives.

Capital allocation decisions, including share repurchases, form part of Bodycote’s broader strategy to deploy cash effectively. The company balances buybacks against investments in capacity expansion, R&D, acquisitions, and debt reduction. The £80 million programme indicates management’s view that current share prices offer attractive value, making buybacks an efficient use of capital. This insight may inform investors’ assessment of the company’s valuation and outlook.

Market Execution and Barclays Bank’s Role

Barclays Bank plc serves as the executing broker for Bodycote’s share repurchase programme, providing institutional market execution expertise. Acting as principal, Barclays ensures purchases comply with all relevant regulations while achieving competitive market pricing. The volume weighted average price of 667.4p during July reflects efficient execution within the intra-week price range. Employing a major financial institution mitigates execution risk and supports best execution standards.

The mandate’s structure, focusing on on-exchange transactions rather than negotiated blocks, integrates buyback activity with normal market trading, avoiding distortions or fairness concerns. Weekly transaction disclosures and detailed trade data illustrate Bodycote and Barclays’ commitment to transparency and accountability. Investors can monitor the relationship between purchase activity and share price trends to assess timing effectiveness.

Outlook and Ongoing Buyback Programme Updates

Bodycote will continue providing weekly updates as the repurchase programme advances through the £40 million initial tranche and potentially into subsequent tranches. This ongoing disclosure offers investors clear visibility into capital deployment and programme execution. The July purchase volume indicates active progress, though no specific completion date for the tranche has been announced. Investors should follow weekly announcements for updates on shares acquired, prices paid, and cumulative tranche progress.

The overall £80 million programme size, split into two £40 million tranches, signals significant planned capital returns over the coming months. The programme’s flexible timing allows management to adjust buyback pace based on market conditions and operational cash flow. The absence of a fixed completion timeline suggests discretion to accelerate or moderate purchases as circumstances evolve. Investors should monitor future disclosures for developments regarding the second tranche and overall programme execution.